180 related articles for article (PubMed ID: 17376931)
1. Dysregulation of HER2/HER3 signaling axis in Epstein-Barr virus-infected breast carcinoma cells.
Lin JH; Tsai CH; Chu JS; Chen JY; Takada K; Shew JY
J Virol; 2007 Jun; 81(11):5705-13. PubMed ID: 17376931
[TBL] [Abstract][Full Text] [Related]
2. Localization of Epstein-Barr virus to infiltrating lymphocytes in breast carcinomas and not malignant cells.
Khan G; Philip PS; Al Ashari M; Houcinat Y; Daoud S
Exp Mol Pathol; 2011 Aug; 91(1):466-70. PubMed ID: 21600202
[TBL] [Abstract][Full Text] [Related]
3. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Pan MH; Lin CC; Lin JK; Chen WJ
J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
[TBL] [Abstract][Full Text] [Related]
4. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.
Okita R; Mougiakakos D; Ando T; Mao Y; Sarhan D; Wennerberg E; Seliger B; Lundqvist A; Mimura K; Kiessling R
J Immunol; 2012 Mar; 188(5):2136-45. PubMed ID: 22301547
[TBL] [Abstract][Full Text] [Related]
5. Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer.
Chakraborty AK; Liang K; DiGiovanna MP
Cancer Res; 2008 Mar; 68(5):1538-45. PubMed ID: 18316619
[TBL] [Abstract][Full Text] [Related]
6. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
7. Establishment and characterization of an in vivo model for Epstein-Barr virus positive gastric carcinoma.
Oh ST; Cha JH; Shin DJ; Yoon SK; Lee SK
J Med Virol; 2007 Sep; 79(9):1343-8. PubMed ID: 17607773
[TBL] [Abstract][Full Text] [Related]
8. Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion.
Ho CH; Chen CL; Li WY; Chen CJ
Carcinogenesis; 2009 Aug; 30(8):1443-51. PubMed ID: 19483191
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of Epstein-Barr virus from latency.
Amon W; Farrell PJ
Rev Med Virol; 2005; 15(3):149-56. PubMed ID: 15546128
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia.
Niller HH; Wolf H; Minarovits J
Semin Cancer Biol; 2009 Jun; 19(3):158-64. PubMed ID: 19429479
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus (EBV)-encoded RNA promotes growth of EBV-infected T cells through interleukin-9 induction.
Yang L; Aozasa K; Oshimi K; Takada K
Cancer Res; 2004 Aug; 64(15):5332-7. PubMed ID: 15289339
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus (EBV) infection and gastric carcinoma: the approach through EBV infected epithelial cell lines.
Sairenji T
Jpn J Infect Dis; 1999 Jun; 52(3):110-2. PubMed ID: 10507989
[TBL] [Abstract][Full Text] [Related]
13. Rheumatoid factors induce signaling from B cells, leading to Epstein-Barr virus and B-cell activation.
Yang L; Hakoda M; Iwabuchi K; Takeda T; Koike T; Kamatani N; Takada K
J Virol; 2004 Sep; 78(18):9918-23. PubMed ID: 15331725
[TBL] [Abstract][Full Text] [Related]
14. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus and breast cancer: state of the evidence for viral carcinogenesis.
Glaser SL; Hsu JL; Gulley ML
Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):688-97. PubMed ID: 15159298
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporin A up-regulates and activates protein kinase C-zeta in EBV-infected and EBV-transformed human B-cells.
Chen C; Johnston TD; Jeon H; Gedaly R; McHugh P; Ranjan D
J Surg Res; 2009 May; 153(1):156-61. PubMed ID: 18486150
[TBL] [Abstract][Full Text] [Related]
17. Role of HER2/HER3 co-receptor in breast carcinogenesis.
Way TD; Lin JK
Future Oncol; 2005 Dec; 1(6):841-9. PubMed ID: 16556064
[TBL] [Abstract][Full Text] [Related]
18. Survival advantage of EBV-associated gastric carcinoma: survivin up-regulation by viral latent membrane protein 2A.
Hino R; Uozaki H; Inoue Y; Shintani Y; Ushiku T; Sakatani T; Takada K; Fukayama M
Cancer Res; 2008 Mar; 68(5):1427-35. PubMed ID: 18316606
[TBL] [Abstract][Full Text] [Related]
19. Role of the RARRES1 gene in nasopharyngeal carcinoma.
Kwok WK; Pang JC; Lo KW; Ng HK
Cancer Genet Cytogenet; 2009 Oct; 194(1):58-64. PubMed ID: 19737656
[TBL] [Abstract][Full Text] [Related]
20. Effects of Epstein-Barr Virus Infection on the Response of Human Breast Cancer Cells to Nicotine.
Rajbongshi L; Noh MH; Kim YS; Hur DY
Anticancer Res; 2021 Jul; 41(7):3449-3458. PubMed ID: 34230140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
